Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption from 1% to 2%. Leerink is optimistic about the company’s revenue and pipeline prospects, which it expects to drive stock price performance. The firm would caveat that it projects higher investment spending growth than consensus models.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Journavx Launch and Durable CF Franchise Underpin Buy Rating and Long-Term Growth Upside
- Vertex Pharmaceuticals: Strong Market Position and Promising Growth Potential Justify Buy Rating
- Vertex Pharmaceuticals: Promising Advancements in Kidney Disease Treatments Drive Buy Rating
- Vertex Pharmaceuticals presents new data on CASGEVY at ASH
- Vertex Pharmaceuticals price target raised to $564 from $516 at Morgan Stanley